Description: Verseon Corporation, a pharmaceutical company, designs and develops novel therapeutics for various diseases in the United States. The company is involved in developing oral anticoagulants for various cardiovascular indications with novel pharmacology; kallikrein inhibitors for the treatment of diabetic macular edema and hereditary angioedema; and novel angiogenesis inhibitors for the treatment of solid tumors, as well as metabolic disorders. Verseon Corporation was founded in 2002 and is headquartered in Fremont, California.
Exchange: NYSE ARCA
Country: US
Currency: US Dollar ($)
Category: Technology
Asset Allocation | |||
---|---|---|---|
Asset Class | Long % | Short % | Net Assets |
Stock US | 87.64 | 0.00 | 87.64 |
Stock non-US | 12.28 | 0.00 | 12.28 |
Other | 0.08 | 0.00 | 0.08 |
Sector Weights | ||
---|---|---|
Sector | Equity % | Relative to Category |
Technology | 62.93 | 76.83 |
Communication Services | 26.20 | 8.04 |
Consumer Cyclicals | 5.26 | 5.36 |
Real Estate | 3.36 | 0.35 |
Healthcare | 2.25 | 1.37 |
World Regions | ||
---|---|---|
Region | Equity % | Relative to Category |
North America | 87.71 | 90.79 |
Asia Emerging | 6.76 | 1.10 |
Asia Developed | 4.11 | 2.58 |
Japan | 1.42 | 0.70 |
Australasia | 0.00 | 0.06 |
Latin America | 0.00 | 0.27 |
United Kingdom | 0.00 | 0.33 |
Europe Developed | 0.00 | 3.57 |
Africa/Middle East | 0.00 | 0.61 |